Mutational activation of the MAP kinase pathway is frequently found in many types of cancer. Recently, activating mutations in the BRAF gene, an important activator of this pathway, have been described in several tumor types including melanoma, colorectal and papillary thyroid cancer. The most frequent mutation in exon 15 (V600E) as well as several other mutations within exons 11 and 15 result in constitutive activation of the oncoprotein.
Materials and methods
Our study aimed to investigate BRAF mutations in 30 human bladder tumors and their adjacent normal tissues. The V600E mutation was screened by PCR/RFLP and exons 11, 14 and 15 of BRAF including intron-exon boundaries were sequenced.
Results
We detected two tumor specimens bearing two different mutations, both of which were found in exon 15. One sample showed the T1799A (V600E) and the other the G1798T (V600L) mutation. The first specimen was stage pT1a and grade II, whereas the second was stage pT2b and grade III. No mutations within the coding region of exons 11, 14, 15 and the intron-exon junctions for the remaining samples were found.
Conclusions
Our results suggest that involvement of BRAF mutations in the development of transitional cell carcinoma of the bladder is infrequent.
Lopez-BeltranA., MontironiR.. Non-invasive urothelial neoplasms: according to the most recent WHO classification.Eur Urol2004; 46: 170–6.
9.
GreeneF.L., SobinL.H.. The staging of cancer: a retrospective and prospective appraisal.CA Cancer J Clin2008; 58: 180–90.
10.
KanellouP., ZaravinosA., ZiogaM.. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.Cancer Lett2008; 264: 145–61.
11.
ZaravinosA., BizakisJ., SpandidosD.A.. RKIP and BRAF aberrations in human nasal polyps and the adjacent turbinate mucosae.Cancer Lett2008; 264: 288–98.
12.
O'NeillE., KolchW.. Conferring specificity on the ubiquitous Raf/MEK signalling pathway.Br J Cancer2004; 90: 283–8.
13.
DuesberyN.S., WebbC.P., Vande WoudeG.F.. MEK wars, a new front in the battle against cancer.Nat Med1999; 5: 736–7.
14.
AvruchJ., KhokhlatchevA., KyriakisJ.M.. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade.Recent Prog Horm Res2001; 56: 127–55.
15.
KimuraE.T., NikiforovaM.N., ZhuZ., KnaufJ.A., NikiforovY.E., FaginJ.A.. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.Cancer Res2003; 63: 1454–7.
16.
NaokiK., ChenT.H., RichardsW.G., SugarbakerD.J., MeyersonM.. Missense mutations of the BRAF gene in human lung adenocarcinoma.Cancer Res2002; 62: 7001–3.
17.
BroseM.S., VolpeP., FeldmanM.. BRAF and RAS mutations in human lung cancer and melanoma.Cancer Res2002; 62: 6997–7000.
18.
YuenS.T., DaviesH., ChanT.L.. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.Cancer Res2002; 62: 6451–5.
19.
StoehrR., BrinkmannA., FilbeckT.. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.Oncol Rep2004; 11: 137–41.
20.
ChoN.Y., ChoiM., KimB.H., ChoY.M., MoonK.C., KangG.H.. BRAF and KRAS mutations in prostatic adenocarcinoma.Int J Cancer2006; 119: 1858–62.
21.
BurgerM., DenzingerS., HammerschmiedC.. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.Eur Urol2006; 50: 1102–9.
22.
SommererF., HenggeU.R., MarkwarthA.R.. Mutations of BRAF and RAS are rare events in germ cell tumours.Int J Cancer2005; 113: 329–35.
23.
NagyA., BalintI., KovacsG.. Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors.Int J Cancer2003; 106: 980–1.
24.
McIntyreA., SummersgillB., SpendloveH.E., HuddartR., HoulstonR., ShipleyJ.. Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors.Neoplasia2005; 7: 1047–52.
25.
UedaM., TojiE., NunobikiO.. Mutational analysis of the BRAF gene in human tumor cells.Hum Cell2008; 21: 13–7.
26.
de JongJ., StoopH., GillisA.J.. Further characterization of the first seminoma cell line TCam-2.Genes Chromosomes Cancer2008; 47: 185–96.
27.
CerniakB., CohenG.L., EtkindP.. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas.Hum Pathol1992; 23: 1199–204.
28.
SaitoS., HataM., FukuyamaR.. Screening of H-ras gene point mutations in 50 cases of bladder carcinoma.Int J Urol1997; 4: 178–85.
29.
SoaresP., TroviscoV., RochaA.S.. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.Oncogene2003; 22: 4578–80.
30.
BoulalasI., ZaravinosA., KaryotisI., DelakasD., SpandidosD.A.. Activation of the RAS family genes in urothelial carcinoma.J Urol2009 (in press).
31.
BasuA., SivaprasadU.. Protein kinase Cepsilon makes the life and death decision.Cell Signal2007; 19: 1633–42.
32.
PerlettiG.P., ConcariP., BrusaferriS., MarrasE., PiccininiF., TashjianA.H.Jr. Protein kinase Cepsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway.Oncogene1998; 16: 3345–8.
